Navigation Links
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Date:12/10/2007

Unique monoclonal antibody successfully targets human leukemic stem cells

ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-clinical activity of a novel monoclonal antibody, in the potential treatment of acute myeloid leukemia (AML).

AML is an aggressive cancer of white blood cells and most commonly occurs in adults. It is usually treated with chemotherapy but the cure rate in adults is only about 30%. About 9,000 deaths from AML occur each year in the United States(1). The novel antibody specifically targets the "core cell" of AML, called the leukemic stem cell (LSC) which was first identified in the laboratory of Professor John Dick, one of the key authors of the study(2). It is currently thought that the resistance of leukemic stem cells to chemotherapy is a major reason for the inability to cure most AML, and that improving the outlook for patients with AML will require elimination of these cells.

The antibody used in the research, called 7G3, was first created by Dr Angel Lopez at the Hanson Centre for Cancer Research in Adelaide, South Australia. It hones in on CD123 (IL-3 receptor alpha chain) on the surface of the LSC, blocking its function, growth and survival. CD123 is found on the surface of normal blood stem cells much less frequently, and 7G3 should therefore have no effect on normal blood cell development.

The research presented at the ASH meeting by key investigator Associate Professor Richard Lock of Children's Cancer Institute Australia for Medical Research in Sydney, describes the results of treatment with 7G3 of irradiated immune-deficient mice with AML.

Two central experiments were undertaken; firstly human AML stem cells were treated with 7G3 and then injected into the mice, which were compared with a control group of mice injected with untreated AML stem cells. The overall survival of treated engrafted mice was significantly improved with the median survival of control group 11.5 weeks versus 24 weeks for the antibody-treated group.

Secondly, 7G3 was administered to mice with established AML. Administration of the antibody to these mice reduced AML dissemination around the body of the mice. The ability of leukemic stem cells from mice treated in this way to reestablish leukemia as secondary transplants into other animals was markedly reduced.

In contrast, exposure to 7G3 had little effect on normal human bone marrow stem cells.

"These results show that 7G3 is able to target LSC's to prevent them from moving around and proliferating in the mice, while at the same time having little effect on normal blood cells," said Dr Lock at the ASH meeting today.

"This is a very exciting finding because it is one of the first drugs that has been designed to specifically target the LSC, rather than simply attacking the cancer cells proliferating in the blood and bone marrow. Hopefully this means that it can fight leukemia without many of the side effects of current drugs. It opens up an exciting new option for the treatment of AML," he said.

CSL wishes to acknowledge the contribution of the University Health Network in Toronto, Canada, The Institute of Medical and Veterinary Science/Hanson Institute for Cancer Research in South Australia, Children's Cancer Institute Australia for Medical Research in Sydney, Australia and the Queensland Institute for Medical Research, Australia, its key collaborators in this important project.

For further information please contact:

Associate Professor Richard Lock

Head, Leukaemia Biology Program

Children's Cancer Institute Australia for Medical Research

Phone: +61 414 769 194

Dr. Darryl Maher

Medical Director

CSL Bioplasma

Phone: +61 412 346 987

Media Contact

Sheila A. Burke OR Jeff Hoyak

Director, Communications & Public Relations MCS Public Relations

Worldwide Commercial Operations, CSL Behring +1-908-884-6753

+1-610-878-4209 jeffh@mcspr.com

Sheila.Burke@cslbehring.com

Media Contact - Australia only

Dr Rachel David

Director of Public Affairs

CSL Limited

Phone: +61 401 775 779

(1) American Cancer Society, Cancer Reference Information.

(2) Lapidot et al Nature 1994

Bonnet & Dick Nature Medicine August 31, 1997.


'/>"/>
SOURCE CSL Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
(Date:5/3/2016)... , May 3, 2016 Intec ... a clinical-stage biopharmaceutical company, today announced the appointment of ... Regulatory Affairs. "Ms. Strauss-Levy has 15 years ... has established an outstanding track record, having supported the ... regulatory approval processes in the United States ...
(Date:5/3/2016)... Global and Chinese Surgical ... overview of the industry that covers definition, applications ... report explores into the international and Chinese players ... Surgical Mesh market spread across 150 pages providing ... is available at http://www.reportsnreports.com/reports/470569-global-and-chinese-surgical-mesh-industry-2016-market-research-report.html . ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
(Date:5/5/2016)... ... 05, 2016 , ... Derrin Doty Group has unveiled the latest charity campaign ... communities west of Seattle. The insurance provider’s caring team has been so moved by ... due to complications from the flu, that they have decided to extend their original ...
(Date:5/5/2016)... ... May 05, 2016 , ... The University of ... to host the 2016 National SACA Leadership Conference on the Portland campus September ... chapter officers to come together and develop skills to be future leaders in ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Vitenas Cosmetic Surgery ... Design Awards, presented by the American Institute of Architects and the Academy of Architecture ... the renowned Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... , ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, ... double board certified and the only facial plastic surgeon in Atlanta to offer ... such as stem cells can be used to provide stabilization to hair transplant results ...
Breaking Medicine News(10 mins):